ValuEngine upgraded shares of Juniper Pharmaceuticals (NASDAQ:JNP) from a sell rating to a hold rating in a report issued on Friday.
Separately, Roth Capital initiated coverage on shares of Juniper Pharmaceuticals in a research note on Tuesday, January 2nd. They issued a buy rating and a $12.00 target price for the company. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $29.00.
Shares of Juniper Pharmaceuticals (JNP) opened at $10.90 on Friday. The firm has a market cap of $118.20, a price-to-earnings ratio of 18.17 and a beta of 0.58. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.68 and a current ratio of 2.00. Juniper Pharmaceuticals has a 52 week low of $3.65 and a 52 week high of $11.15.
Several hedge funds have recently added to or reduced their stakes in JNP. Bailard Inc. purchased a new position in shares of Juniper Pharmaceuticals in the 4th quarter valued at about $267,000. Dimensional Fund Advisors LP increased its holdings in shares of Juniper Pharmaceuticals by 19.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 86,866 shares of the specialty pharmaceutical company’s stock valued at $395,000 after purchasing an additional 13,991 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Juniper Pharmaceuticals by 59.9% in the 4th quarter. Acadian Asset Management LLC now owns 67,269 shares of the specialty pharmaceutical company’s stock valued at $327,000 after purchasing an additional 25,201 shares in the last quarter. Algert Global LLC increased its holdings in shares of Juniper Pharmaceuticals by 20.4% in the 3rd quarter. Algert Global LLC now owns 144,565 shares of the specialty pharmaceutical company’s stock valued at $658,000 after purchasing an additional 24,530 shares in the last quarter. Finally, Nationwide Fund Advisors increased its holdings in shares of Juniper Pharmaceuticals by 5,500.0% in the 2nd quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock valued at $283,000 after purchasing an additional 55,000 shares in the last quarter. Institutional investors own 39.67% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3258290/juniper-pharmaceuticals-jnp-raised-to-hold-at-valuengine.html.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.